Valganciclovir Hcl Articles

Cytomegalovirus infections market completely controlled by Roche's Valcyte

5 February 2013

New Zealand's PHARMAC decisions on Roche products

11 October 2012

US FDA clears Roche’s Valcyte to prevent CMV disease in pediatric patients

2 September 2009

Roche reports 7% growth for 1st qtr, despite recession, with Genentech merger looming

17 April 2009

Roche's Valcyte works up to 200 days; trial

23 February 2009

Challenge to Indian patent on Roche's Valcyte by local firms

7 July 2008

Roche pleases investors with 15% hike in first-half sales and strong guidance

30 July 2007

Valcyte as effective as ganciclovir in CMV

14 May 2007

Israel's 2005 NHI drugs basket creates precedents for funding and registration

16 May 2005

Positive new data for Roche's ganciclovir

31 May 2004

Roche's Valcyte comparable to Cytovene

9 June 2003

Roche's Fuzeon cleared in Switzerland

2 June 2003

Roche's Valcyte approved for CMV in Europe

18 March 2002

Update: Roche's Valcyte gets 1st EU approval in Holland

2 October 2001

Roche's Valcyte approved in Holland

27 September 2001

Roche's oral anti-CMV prodrug approved

5 April 2001

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end